Blood pressure variability (BPV) has been increasingly recognized as a prognostic factor influencing the probabilities of future cardiovascular events. 1 BPV can be measured at long term, i.e., fluctuations in blood pressure values in different visits during a certain period of time. In addition, short-term variability can be obtained through different parameters from a 24-hour ambulatory blood pressure monitoring. Such parameters include the decline in blood pressure that occurs during sleep, as well as different measures considering fluctuations of blood pressure during the 24-hour monitoring. SDs and coefficient of variation (CV) of 24-hour, daytime, and nighttime blood pressure, as well as average real variability (ARV) (mean differences between 2 consecutive measures during the whole 24-hour period) have been proposed as short-term variability measures with potential prognostic importance. [2] [3] [4] Both mineralocorticoid receptor antagonists and sympathetic renal denervation (SRD) are treatment options for patients with resistant hypertension. 5 Randomized controlled trials against placebo 6 or compared to other antihypertensive drugs, such as beta blockers or alpha blockers 7 have demonstrated that spironolactone is the drug of choice for patients not controlled on at least 3 antihypertensive medications. In addition, studies with SRD have suggested a possible role in reducing BP in such patients, 8, 9 although the lack of a significant superiority against a sham procedure in a double-blind, randomized trial, 10 has raised some controversy regarding the efficacy of the ablation of sympathetic renal nerves.
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We have previously reported that spironolactone was superior to renal denervation in reducing 24-hour ambulatory blood pressure in patients with resistant hypertension. 11 Using the data from this randomized comparative trial, we examined the effect of both treatments on BP circadian pattern and BPV.
PATIENTS AND METHODS
The DENERVación en HiperTensión Arterial (DENERVHTA) study is a prospective, multicentre, openlabel, randomized, controlled trial (clinicaltrials.gov identifier: NCT02039492), comparing renal denervation vs. spironolactone as add-on treatments in patients with true resistant hypertension. Details on patient recruitment and clinical characteristics have been reported elsewhere. 11 Briefly, hypertensive patients between 18 and 80 years with office systolic blood pressure (SBP) ≥150 mm Hg and 24-hour SBP ≥140 mm Hg while on treatment with 3 or more full-dose antihypertensive medications, one of them a diuretic, but without mineral corticoid receptor antagonists, were randomized 1:1 to SRD (one single operator, median 10 shots) or spironolactone, 50 mg/day, added to current antihypertensive treatment. The primary outcome was the difference between treatments in the change of 24-hour SBP at 6 months of randomization. Additional analyses reported here are focused on daytime and nighttime BP, circadian profiles, and BPV.
Calculation of different parameters derived from 24-hour ambulatory blood pressure monitoring
A 24-hour ambulatory blood pressure monitoring was performed before randomization and repeated after 6 months. The SpaceLabs 90207 device was used with the monitor placed between 08:00 and 10:00 and programmed to measure BP every 20 minutes throughout the 24-hour period. A valid record was considered when at least 80% of programmed measures were obtained. Otherwise, the procedure was repeated within the following 7 days.
Diurnal and nocturnal blood pressures and circadian patterns
Diurnal and nocturnal periods were defined by using narrow windows. Daytime period was considered from 08:00 to 22:00 and nighttime period from 00:00 to 06:00. Nightto-day ratios (in %) for SBP and diastolic blood pressures (DBPs), as well as for heart rate were calculated.
Measurements of blood pressure and heart rate variability SD and CVs (CV = SD * 100/BP) were calculated for SBP and DBP, as well as for heart rate, for 24-hour, daytime, and nighttime periods.
Weighted SD (WSD) was calculated using the following formula 2 :
Furthermore, ARV was calculated as the average of the differences (in absolute value) between consecutive BP measurements. 3 
Statistical analysis
Values are expressed as means ± SDs. The difference between baseline and 6 months after randomization was calculated for all the variables of interest. General linear models were used for the comparison between treatment groups, after adjustments for baseline values (comparison of diurnal, nocturnal, and nocturnal fall), or after adjustments for differences in BP or in HR (for SD, CV, WSD, and ARV). SPSS for Windows version 19.0 software (IBM, Armonk, NY) was used for statistical analysis.
RESULTS
Twenty-four randomized patients had complete data of ambulatory blood pressure monitoring at both baseline and after 6 months. They were treated with spironolactone (N = 13) or with SRD (11). They were 15 men and 9 women with a mean age of 64 ± 7 years. Table 1 shows baseline main clinical parameters in both groups. Although differences were not significant, baseline 24-hour BP was slightly higher in the spironolactone group. For this reason, baseline BP was used as a covariate in all further comparisons between groups. Baseline antihypertensive treatment was comparable between groups (Supplementary Table S1) Spironolactone was superior to renal denervation in reducing daytime SBP (25.6 ± 17.0 vs. 3.4 ± 12.8 mm Hg, P = 0.006) and DBP (10.3 ± 8.4 vs. 1.8 ± 8.3 mm Hg, P = 0.006). The reduction in nighttime BP was also more pronounced for spironolactone, although with marginal statistical significance (Table 2 ). No differences were observed in changes in daytime or nighttime heart rate or in night-to-day ratios for SBP, DBP, or HR. Likewise, the proportion of dippers/nondippers or its modification did not differ between treatments (Supplementary Figure S1) . Table 3 shows changes in SD and CV for 24-hour, day, and night periods in both groups of treatment. No differences were observed in changes in SBP or HR. In contrast, there were significant differences in both SD and CV for DBP, for all periods (24-hour, daytime, and nighttime), with a reduction in all such parameters in the group treated with SRD in comparison to patients treated with spironolactone, after adjustments for absolute BP differences. These results were confirmed by calculating WSD (average of daytime and nighttime SD adjusted for the duration of each period), or by the ARV. In both cases, values for DBP were reduced in patients undergoing renal denervation, in comparison to spironolactone-treated patients (−2.0 ± 3.3 vs. 0.4 ± 1.9 mm Hg, P = 0.013 for WSD and −1.0 ± 1.8 vs. 0.2 ± 1.0 mm Hg, P = 0.023 for ARV; Table 4 ).
DISCUSSION
The present analysis from the randomized DENERVHTA study shows a divergent impact of spironolactone and SRD on BP reduction and BPV. Spironolactone was clearly more efficacious than SRD in reducing daytime and nighttime SBP and DBP, confirming previous reported results on 24-hour BP. 11 In contrast, as regards short-term BPV, SRD-reduced DBP variability (SD of 24 hours both crude and weighted, daytime, and nighttime, as well as ARV) in comparison to spironolactone. No differences were observed between treatments on HR, or on SBP and HR variabilities. Spironolactone is now considered the drug of choice for treatment of hypertensive patients resistant to first-line drug therapies (3-drug combinations, including a diuretic). [5] [6] [7] Two randomized trials against placebo 6 or in comparison to other second-line drugs (beta blockers and alpha blockers) 7 have demonstrated a clear superiority of spironolactone. In addition, SRD has been proposed as a nonpharmacological alternative for treatment of the same group of patients. Although a randomized study against a sham procedure did not achieved the predicted BP difference, 10 some methodological issues have been raised in relation to these results. 12 Other randomized studies against a control group 8 or against pharmacological treatment intensification 9,13 have both suggested a beneficial role in BP reduction. Furthermore, the results of a global registry with almost 1,000 patients have recently been reported, consistent with a moderate BP reduction in patients undergoing SRD. 14 The present study, which compares head-to-head both treatment options, demonstrates that spironolactone is more effective than renal denervation in reducing daytime and nighttime BP, confirming previous results on 24-hour (the primary outcome measure of the DENERVHTA study). 11 This was examined by using narrow windows for day and night periods, thus avoiding the frequently observed overlapping with broader or dairy-based periods. The superiority of spironolactone in BP reduction was not accompanied by differences in the circadian pattern, as changes in the nightto-day ratio of BP were minimal and similar between groups.
In addition, the effect of both treatments on BPV did not run in parallel to changes in BP. Renal denervation significantly reduced diastolic BPV in comparison to spironolactone. This was evident in all the BPV parameters (crude SD and CV obtained in daytime and nighttime periods, as well as in the whole 24 hours, WSD, and ARV). Although none of the systolic BPV parameters showed differences between groups, again the reduction tended to be more pronounced in the renal denervation group.
As far as we know, there are no reports on BPV changes with spironolactone. In the ASPIRANT trial, 6 differences in SBP between spironolactone and placebo, were 5 mm Hg more pronounced at nighttime than at daytime, thus suggesting a possible effect in reducing night-to-day ratios, although this was not specifically examined in the report.
In contrast, at least 3 previous reports have examined BPV in patients treated with SRD, with conflicting results. [15] [16] [17] Miroslawska et al. 15 have reported a significant reduction in BPV parameters (both systolic and diastolic) after 6 months of SRD in 23 resistant hypertensive patients. In contrast, another study from Tsioufis et al., 16 in 31 patients, did not find any effect on BPV. A third study by Ewen et al., 17 with 84 patients included, reported reductions in 24-hour SD and CV, as well as in ARV, after 3 months of renal denervation. Some of these effects were maintained also after 6 months. Interestingly, the reduction in BPV indexes were also observed in patients classified as nonresponders. None of these studies were randomized or had a control group. Our results add evidence to those previously reported, supporting a beneficial effect of SRD on BPV. In contrast to previous studies, this is the first time that such results are obtained by a head-to-head comparison with another group of treatment, in a randomized study.
Increased BPV is considered a risk factor for cardiovascular mortality and morbidity, and it is also associated with the degree of organ damage. 1 Although the consideration of 24-hour SD or CV are highly dependent on absolute BP (SD) and on the degree of the nocturnal BP fall (both SD and CV), the use of WSD and ARV have been proposed as better indexes of BPV, able to overcome such inconvenience and adding prognostic value. 2, 3 Mechanisms influencing short-term variability are poorly understood, but include both behavioral influence and intrinsecal BP mechanisms of regulation. Among them, sympathetic nervous system activity is probably one of the most important. 18 SRD has been developed as a technique to reduce sympathetic inflow and outflow to and from renal nerves. Some data suggest that it reduces the global sympathetic tone, as demonstrated by a decrease in muscle sympathetic nerve activity. 19 This reduction could be the explanation of a reduction in BPV even in patients with relatively weak BP response, an effect not shared with spironolactone, even in the presence of a larger BP reduction.
This study has limitations. First of all, the small sample size does not allow to totally discard changes due to chance. Second, differences in BPV are constricted to DBP, whereas differences in SBP were not significant. We cannot provide an explanation for these discrepancies, but the greater stability of DBP determination could be responsible for the detection significant differences only in this parameter. In contrast, this is the first time renal denervation is compared in a randomized trial with spironolactone, considered the first-choice pharmacological treatment of resistant hypertension. Thus, results on BPV are more consistent than previous reports, with the inclusion of a parallel treatment group. Moreover, changes in BPV produced by renal denervation are not dependent on BP reduction, as such reduction was clearly favorable to spironolactone.
In conclusion, spironolactone is more effective than renal denervation in reducing day and night BP, confirming previous results on 24-hour BP. In contrast, diastolic BPV was reduced by renal denervation in comparison to spironolactone. Since BPV appears to have prognostic significance independent of the absolute BP values, the effect of renal denervation on BPV needs to be further investigated in relation to the potential benefits with respect to both the reduction of cardiovascular events, as well as the selection of candidates in whom this technique could be more appropriate.
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